CRISPR Therapeutics AG (NASDAQ: CRSP) open the trading on Wednesday, with a bit cautious approach as it glided -0.56% to $49.59, before settling in for the price of $49.87 at the close. Taking a more long-term approach, CRSP posted a 52-week range of $37.55-$91.10.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that the giant of the Healthcare sector posted annual sales growth of 33402.13% over the last 5 years. Meanwhile, its Annual Earning per share during the time was 10.83%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -188.67%. This publicly-traded company’s shares outstanding now amounts to $85.17 million, simultaneously with a float of $81.47 million. The organization now has a market capitalization sitting at $4.22 billion. At the time of writing, stock’s 50-day Moving Average stood at $50.94, while the 200-day Moving Average is $60.86.
CRISPR Therapeutics AG (CRSP) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Biotechnology industry. CRISPR Therapeutics AG’s current insider ownership accounts for 4.34%, in contrast to 63.33% institutional ownership. According to the most recent insider trade that took place on Jun 21 ’24, this organization’s Chief Operating Officer sold 3,366 shares at the rate of 56.09, making the entire transaction reach 188,799 in total value, affecting insider ownership by 6,745. Preceding that transaction, on Apr 15 ’24, Company’s Chief Executive Officer sold 19,582 for 59.91, making the whole transaction’s value amount to 1,173,232. This particular insider is now the holder of 208,122 in total.
CRISPR Therapeutics AG (CRSP) Earnings and Revenue Records
CRISPR Therapeutics AG’s EPS decrease for this current 12-month fiscal period is -188.67% and is forecasted to reach -4.86 in the upcoming year.
CRISPR Therapeutics AG (NASDAQ: CRSP) Trading Performance Indicators
Let’s observe the current performance indicators for CRISPR Therapeutics AG (CRSP). It’s Quick Ratio in the last reported quarter now stands at 15.73. The Stock has managed to achieve an average true range (ATR) of 2.19. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 20.89.
In the same vein, CRSP’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -3.23, a figure that is expected to reach -1.42 in the next quarter, and analysts are predicting that it will be -4.86 at the market close of one year from today.
Technical Analysis of CRISPR Therapeutics AG (CRSP)
[CRISPR Therapeutics AG, CRSP] recent stats showed that its last 5-days Average volume was poorer than the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 79.30% While, its Average True Range was 2.16.
Raw Stochastic average of CRISPR Therapeutics AG (CRSP) in the period of the previous 100 days is set at 25.22%, which indicates a major fall in contrast to 72.00% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 41.37% that was lower than 48.17% volatility it exhibited in the past 100-days period.
